Losses
-€26,312 in two years
The 2024 and 2025 financial years closed with a loss. 2025 was the heaviest.
EZI Biolab
Lifetime
11 annual accounts with figures on one time axis, 13 filings since 2013Gross marginpeak €192,770 (2016)
€79,847▼ 18.5%
Resultlowest -€35,256 (2022)
-€20,694▼ €15,077
Equitypeak €213,178 (2017)
€152,455▼ 12.0%
Debts
€447,287▼ 5.9%
Board2 names since 2012
2 directorsMOURAD Isabelle Jamila Sophie and 1 other
Documentsfilings and deeds
04-06-202657 days before the deadline
2025micro format
Gross margin from €97,922 to €79,847Loss of €20,694
Key points
from the 2025 annual accountsTurnover
≈ €310,000 estimated
The accounts state no turnover.
Debts
€447,287 75% of the balance sheet
Financial debts 68%Suppliers 3%Taxes and wages 7%Other 23%
Of this, €143,303 falls due within a year.
Staff
2 employees on 31-12-2025
In 2025, 1 person joined and 0 left.
Filings
13 annual accounts since 2013
The last five annual accounts were filed 37 to 61 days before the end of the period.
Position in the sector
-€20,694
Lower net result than 89% of companies in wholesale trade. Sector median €5,636 · 13,785 companies.
Checked score
90
Excellent
Financially stronger than 37% of micro companies in wholesale trade (NACE 46)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 26,900 companies (NACE 46, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%lowest value
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026highest value
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Loss of €20,694, the second in a row (financial year 2025)
lowers risk
Size: total assets €599,741
Figures for financial year 2025 (filed on 04-06-2026)
Founded in 2012
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 36% of them on solvency, 57% on liquidity, 32% on profitability and 24% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,166 companies had the same profile as EZI Biolab has now. Each dot stands for 6 companies, two years later.
94.1%
were still trading
3.0%
stopped another way
2.5%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of EZI Biolab itself is lower: 0.1% within 12 months. It rests on far more data about EZI Biolab than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,166 companies, not a prediction for EZI Biolab. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €13,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.01 (1.14 in 2024), below the usual 1.5. Short-term debt is 23.9% and cash 8.7% of total assets. 74.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€20,694
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 04-06-2026, 57 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
57 days early
2024
51 days early
2023
37 days early
2022
59 days early
2021
61 days early
2020
50 days early
2019
64 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 54 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 4 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0500516337
Company renamed from EZI CONSULTING to EZI Biolab
Changes of role: MOURAD Isabelle Jamila Sophie (director) and CAVALIER Etienne Albert José Marie Léopold Ghislain (director) · General meeting of 30-08-2021 · Gazette deed
Incorporation
published on 14-11-2012 · Gazette deed
First establishment
Avenue de l'Energie 31, Ans
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| EZI Biolab Oupeye | €599,741 | €79,847 | 25.4% | - |
| CF Pharma Beaumont | €469,314 | €89,505 | 16.7% | - |
| Appono Mechelen | €569,162 | €100,515 | 35.0% | 0.2 |
| ARNA LOGISTICS Ath | €502,130 | €99,288 | -27.4% | - |
| AMOPHAR Schelle | €401,301 | €83,196 | -253.6% | 1.8 |
| CAWET Orthopédie Chimay | €392,771 | €95,308 | 17.7% | - |
| Rainbow-Flash Puurs-Sint-Amands | €421,857 | €104,032 | 95.1% | - |
These companies have the same main activity as EZI Biolab: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €393,000 and €569,000, founded between 2010 and 2015.
Official details
Source: KBO- Status
- Active since 02-11-2012Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460and 4 others
- Establishment unit
- 2.215.186.3274432 Ans, since 22-10-2012
- Financial year end
- 31 December
- Peppol
- Reachable since 22-12-2025
Annual accounts 2025
- Total assets
- €599,741▼ 7.5%
- Employeeson 31-12-2025
- 2▲ 100%
- Filing
- Filed on 04-06-2026, 57 days before the end of the filing period
Insights on EZI Biolab
EZI Biolab files the micro format. That format states no turnover. The gross margin fell from €80,625 in 2015 to €79,847 in 2025.
The balance sheet grew most from 2021 to 2022 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about EZI Biolab
- What is the company number of EZI Biolab?
- The company number of EZI Biolab is 0500.516.337. The VAT number is the same number with BE in front: BE 0500.516.337.
- Where is EZI Biolab based?
- The registered office is at Rue du Broux 37, 4680 Oupeye.Company details
- What does EZI Biolab do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of EZI Biolab?
- EZI Biolab is a private limited company (BV).
- When was EZI Biolab founded?
- EZI Biolab was founded on 02-11-2012.
- Is EZI Biolab still active?
- Yes, EZI Biolab is an active enterprise in the KBO register.
- How many employees does EZI Biolab have?
- EZI Biolab had an average of 1.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of EZI Biolab?
- The turnover in financial year 2025 is ≈ €310,000. This figure is estimated from the gross margin of €79,847 and 33 comparable companies (NACE 464). It probably lies between €160,000 and €430,000.
- Is EZI Biolab profitable?
- In financial year 2025, EZI Biolab made a loss of €20,694.
- Where can I find the annual accounts of EZI Biolab?
- EZI Biolab filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EZI Biolab due?
- EZI Biolab must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.